Design and immunogenicity of a novel synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein.

@article{Ntumngia2012DesignAI,
  title={Design and immunogenicity of a novel synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein.},
  author={Francis B. Ntumngia and John H Adams},
  journal={Clinical and vaccine immunology : CVI},
  year={2012},
  volume={19 1},
  pages={30-6}
}
The Duffy binding protein is considered a leading vaccine candidate against asexual blood-stage Plasmodium vivax. The interaction of P. vivax merozoites with human reticulocytes through Duffy binding protein (DBP) and its cognate receptor is vital for parasite infection. The ligand domain of DBP (DBPII) is polymorphic, showing a diversity characteristic of selective immune pressure that tends to compromise vaccine efficacy associated with strain-specific immunity. A previous study resolved that… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

Broadly neutralizing epitopes in the Plasmodium vivax vaccine candidate Duffy Binding Protein.

Proceedings of the National Academy of Sciences of the United States of America • 2016

References

Publications referenced by this paper.
Showing 1-10 of 45 references

Plasmodium vivax: merozoite antigens, the Duffy blood group, and erythrocyte invasion.

Progress in clinical and biological research • 1989
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…